PDCD1 and neoplasm: These metabolites increase myeloid-derived suppressor cells (MDSCs) and regulatory T cells, upregulate PD-1 expression on cytotoxic T cells, and decrease tumor-infiltrating lymphocytes, rendering the TME immunosuppressive.3